Cargando…
Treating neovascular age-related macular degeneration in the era of COVID-19
Autores principales: | Antaki, Fares, Dirani, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171913/ https://www.ncbi.nlm.nih.gov/pubmed/32318805 http://dx.doi.org/10.1007/s00417-020-04693-w |
Ejemplares similares
-
Revisiting the Utility of Dilated Fundus Exams in Patients with Neovascular Age-Related Macular Degeneration Receiving Regular Intravitreal Injections
por: Antaki, Fares, et al.
Publicado: (2021) -
Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up
por: Javidi, Simon, et al.
Publicado: (2020) -
Fear Associated with COVID-19 in Patients with Neovascular Age-Related Macular Degeneration
por: Rozon, Jean-Philippe, et al.
Publicado: (2021) -
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept
por: Parvin, Parmis, et al.
Publicado: (2017) -
Combined photodynamic therapy and intravitreal ranibizumab as treatment for extrafoveal choroidal neovascularization associated with age-related macular degeneration
por: Chhablani, Jay Kumar
Publicado: (2010)